# Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease

> **NCT02949375** · PHASE2 · TERMINATED · sponsor: **GRI Bio Operations, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Chronic Liver Disease

## Interventions

- **DRUG:** Placebo Comparator
- **DRUG:** Active Comparator:4.5mg GRI-0621
- **DRUG:** Active Comparator: 6.0mg GRI-0621

## Key facts

- **NCT ID:** NCT02949375
- **Lead sponsor:** GRI Bio Operations, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09
- **Primary completion:** 2018-11
- **Final completion:** 2019-06
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Administrative decision
- **Last updated:** 2019-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02949375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02949375, "Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02949375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*